Impact of Tigecycline on C. difficile Outcomes: Case Series and Propensity-Matched Retrospective Study

Abstract
This case series and propensity-matched cohort study on the use of tigecycline in Clostridioides difficile infection (CDI) evaluated the effect of tigecycline on 30-day mortality. Adjusted for ATLAS Score, hypotension, treatment time period, and serum lactate, tigecycline did not significantly improve 30-day mortality (odds ratio: 0.89; 95% confidence interval: 0.25-3.12; P = 0.853). A randomized controlled trial is needed to determine efficacy and safety of tigecycline in severe or refractory CDI.
Funding Information
  • HHS | NIH | National Center for Advancing Translational Sciences (UL1TR003015, KL2TR003016)
  • HHS | National Institutes of Health (K23AI163368)
  • HHS | National Institutes of Health (AI145322)

This publication has 23 references indexed in Scilit: